[
  {
    "ts": null,
    "headline": "Enbridge: \"Quintuple Vortex\" Exemplified",
    "summary": "Enbridge fails key quality metrics: high debt, slow growth, high capex, unsustainable dividends, and significant shareholder dilution create a...",
    "url": "https://finnhub.io/api/news?id=67bc5dc57d65348054bae9585774b4cb470951dd89e9ae12ce4615b5012b5d9c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749037523,
      "headline": "Enbridge: \"Quintuple Vortex\" Exemplified",
      "id": 135010682,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1249580599/image_1249580599.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Enbridge fails key quality metrics: high debt, slow growth, high capex, unsustainable dividends, and significant shareholder dilution create a...",
      "url": "https://finnhub.io/api/news?id=67bc5dc57d65348054bae9585774b4cb470951dd89e9ae12ce4615b5012b5d9c"
    }
  },
  {
    "ts": null,
    "headline": "Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer",
    "summary": "StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.",
    "url": "https://finnhub.io/api/news?id=63d73e2c0567bfcc4b8c5f5dfc14eeca898b92c4bcf4163ad70b778239d63554",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749027420,
      "headline": "Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer",
      "id": 135010884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.",
      "url": "https://finnhub.io/api/news?id=63d73e2c0567bfcc4b8c5f5dfc14eeca898b92c4bcf4163ad70b778239d63554"
    }
  },
  {
    "ts": null,
    "headline": "EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma",
    "summary": "The decision follows the Committee for Medicinal Products for Human Use’s positive opinion in April 2025.",
    "url": "https://finnhub.io/api/news?id=cdca8f1b0e2e113f708d0b08d590314775c3ccc565cc0559b308994a3f3da01a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749026839,
      "headline": "EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma",
      "id": 135008341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The decision follows the Committee for Medicinal Products for Human Use’s positive opinion in April 2025.",
      "url": "https://finnhub.io/api/news?id=cdca8f1b0e2e113f708d0b08d590314775c3ccc565cc0559b308994a3f3da01a"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are The High-Yield Dividend Investor's Best Friend",
    "summary": "There are some high-yield stocks available today that check all of my boxes. Check out some of my top high-yield picks of the moment.",
    "url": "https://finnhub.io/api/news?id=43eea124524c4bc53ba205c73a924de8f351d75ba78c47c476b481f7ba630ac9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749020700,
      "headline": "These Stocks Are The High-Yield Dividend Investor's Best Friend",
      "id": 135007765,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2155273048/image_2155273048.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "There are some high-yield stocks available today that check all of my boxes. Check out some of my top high-yield picks of the moment.",
      "url": "https://finnhub.io/api/news?id=43eea124524c4bc53ba205c73a924de8f351d75ba78c47c476b481f7ba630ac9"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks in Hot Water",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 12.3%. This drawdown was noticeably worse than the S&P 500’s 1.9% loss.",
    "url": "https://finnhub.io/api/news?id=64e005b820af58c1b2d286ee0bdcb4100d9099b5aa241551d2b955e5b7829d36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749011902,
      "headline": "3 Healthcare Stocks in Hot Water",
      "id": 135009088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 12.3%. This drawdown was noticeably worse than the S&P 500’s 1.9% loss.",
      "url": "https://finnhub.io/api/news?id=64e005b820af58c1b2d286ee0bdcb4100d9099b5aa241551d2b955e5b7829d36"
    }
  },
  {
    "ts": null,
    "headline": "PFIZER INC : Bernstein reaffirms its Neutral rating",
    "summary": "Analyst Justin Smith from Bernstein research gives the stock a Neutral rating. The target price remains set at USD 30.",
    "url": "https://finnhub.io/api/news?id=e8b10074e3ae6aaa6f35eac93bc982ef721aeb225683805dbf4cf602e0004d1c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749006909,
      "headline": "PFIZER INC : Bernstein reaffirms its Neutral rating",
      "id": 135006268,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Analyst Justin Smith from Bernstein research gives the stock a Neutral rating. The target price remains set at USD 30.",
      "url": "https://finnhub.io/api/news?id=e8b10074e3ae6aaa6f35eac93bc982ef721aeb225683805dbf4cf602e0004d1c"
    }
  }
]